---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-250130"
form_type: "8-K"
ticker: "CELU"
cik: "0001752828"
company_name: "Celularity Inc"
filed_at: "2022-09-23T23:59:59+00:00"
generated_at: "2026-06-23T07:47:48.708411+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Celularity retains former President Dr. Pecora as consultant and advisory co-chair

## Summary
- Dr. Pecora resigned as President effective Aug 31, 2022; consulting agreement signed Sept 21, 2022.
- Consulting fee: $10,000/month for six-month term, automatically renews for one additional six-month term.
- Separate scientific/clinical advisor agreement effective Sept 1, 2022: $10,000/month plus $125,000 in RSUs vesting over four years.
- Advisor agreement has a one-year term and may be renewed annually by mutual agreement.
- No other executive changes disclosed; Pecora remains involved in clinical development and advisory board.

## SEC filing metadata
- accession: 0001193125-22-250130
- form_type: 8-K
- ticker: CELU
- cik: 0001752828
- company_name: Celularity Inc
- filed_at: 2022-09-23T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1752828/000119312522250130/0001193125-22-250130-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1752828/000119312522250130/d255337d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-250130
- JSON: https://secwatch.observer/filing/0001193125-22-250130.json
- Plain text: https://secwatch.observer/filing/0001193125-22-250130.txt

## Key facts
- Executive change
  Andrew L. Pecora resigned as President at Celularity Inc.
  - Action: resigned
  - Role: President
  source text: As previously disclosed in the Current Report on Form 8-K filed by Celularity Inc, or Celularity, with the Securities and Exchange Commission, or the SEC, on July 20, 2022, Andrew L. Pecora, M.D., F.A.C.P., resigned as Celularity’s President effective as of August 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1752828/000119312522250130/0001193125-22-250130-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.